Generic Name and Formulations:
Propylthiouracil 50mg; scored tabs; contains docusate sodium.
Various generic manufacturers
Indications for Propylthiouracil:
Give in 3 equally divided doses every 8hrs. Initially 300mg/day. Severe conditions: initially 400mg/day; max 900mg/day. Maintenance: 100–150mg/day.
Give in 3 equally divided doses every 8hrs. <6yrs: not recommended. ≥6yrs: initially 50mg/day; may upward titrate based on response, TSH, and free T4 levels.
Should be reserved for those intolerant to methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments. Risk of severe liver injury and acute liver failure. Monitor for signs of hepatic dysfunction esp. in the 1st 6 months of therapy; discontinue if occur and obtain LFTs and ALT/AST levels. Discontinue if agranulocytosis, aplastic anemia, ANCA-positive vasculitis, hepatitis, interstitial pneumonitis, fever, or exfoliative dermatitis is suspected. Monitor thyroid function periodically, prothrombin time esp. before surgical procedures. Pregnancy (Cat.D). Nursing mothers.
May potentiate anticoagulants. Caution with other drugs that may cause agranulocytosis. May need to reduce doses of beta-blockers, digitalis glycosides, theophylline at euthyroid state.
Rash, urticaria, GI upset, arthralgia, paresthesia, taste loss/perversion, hair loss, myalgia, headache, drowsiness, edema, vertigo, jaundice, blood dycrasias, lupus-like syndrome, drug fever, hepatitis, hypoprothrombinemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline